Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To Purchase # 7949S

7949S 1 Kit (16 multiplexed assays)

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Figure 1. Screening of cell lines using the PathScan® RTK Signaling Antibody Array (Fluorescent Readout) #7949 reveals various phosphorylated RTKs and signaling nodes. Karpas-299 and K562 cells were lysed without starvation or treatment. The fluorescent image (lower panel) and the quantification of that image (upper panel) are shown.

Learn more about how we get our images

Figure 2. Treatment of MCF-7 cells with IGF-I stimulates phosphorylation of IGF-IR at tyrosine residues, Akt at Ser473 and p44/42 MAPK at Thr202/Tyr204 as detected by the PathScan® RTK Signaling Antibody Array Kit (Fluorescent Readout) #7949. MCF-7 cells were starved for 24 hours, then treated with 100 ng/ml IGF-I #3093 for 5 minutes at 37ºC. The fluorescent image (lower panel) and the quantification of that image (upper panel) are shown.

Learn more about how we get our images

Figure 3. Treatment of A431 cells with EGF stimulates phosphorylation of EGFR, Akt, p44/42 MAPK and Stat3 as detected by the PathScan® RTK Signaling Antibody Array Kit (Fluorescent Readout) #7949. A431 cells were starved for 24 hours and treated with 100 ng/ml hEGF #8916 for 5 or 40 minutes. In some cases, cells were treated with either 1 μM wortmannin #9951 for 1 hour or 1 μM gefitinib for 2 hours before EGF stimulation. Fluorescence intensities obtained from the array are shown in the top panel, while western blots are shown in the bottom panel.

Learn more about how we get our images

Figure 4. The relationship between lysate protein concentration from untreated and IGF-I treated MCF-7 cells and the relative fluorescence of phospho-IGF-IR (panTyr), phospho-Akt (Ser473) and phospho-p44/42 (Thr202/Tyr204) is shown. MCF-7 cells were starved for 24 hours, then treated with 100 ng/ml IGF-I #3093 for 5 minutes at 37ºC.

Learn more about how we get our images

Figure 5. Target map of the PathScan® RTK Signaling Antibody Array Kit (Fluorescent Readout)

Learn more about how we get our images
Image
Product Includes Quantity Cap Color
Array Slides
Multi-Well Gasket
Sealing Tape 2 sheets
Detection Antibody Cocktail (10X ) 300 µl White
DyLight 680TM-linked Streptavidin (10X) 300 µl Brown
Array Blocking Buffer 5 ml Red
Array Diluent Buffer 15 ml Blue
20X Array Wash Buffer 15 ml White
Cell Lysis Buffer (10X) 9803 15 ml Clear

Product Usage Information

Storage: Kit should be stored at 4°C with the exception of Lysis Buffer, which is stored at –20°C (packaged separately).

Product Description

The PathScan® RTK Signaling Antibody Array Kit (Fluorescent Readout) is a slide-based antibody array product founded upon the sandwich immunoassay principle. The array kit allows for the simultaneous detection of 28 receptor tyrosine kinases and 11 important signaling nodes when phosphorylated at tyrosine or other residues. Target-specific capture antibodies, biotinylated protein (positive control) and nonspecific IgG (negative control) have been spotted in duplicate onto nitrocellulose-coated glass slides. Each kit contains two 8-pad slides, allowing the user to test up to 16 samples. Cell lysate is incubated on the slide followed by a biotinylated detection antibody cocktail. Streptavidin-conjugated DyLight 680® is then used to visualize the bound detection antibody. A fluorescent image of the slide can then be captured with a digital imaging system and spot intensities quantified using array analysis software.


Specificity / Sensitivity

Cell Signaling Technology's PathScan® RTK Signaling Antibody Array Kit detects the indicated RTKs and signaling nodes only when phosphorylated at tyrosine or specified residues (see Array Target Map). No significant crossreactivity has been observed between targets, with the exception of some crossreactivity of the FLT3 antibody with phosphorylated EphB3. In addition, Stat1 (Tyr701) and Stat3 (Tyr705) may be detected when phosphorylated at other tyrosine sites within the proteins. This kit is optimized for cell lysates diluted to a total protein concentration between 0.2 and 1 mg/ml (see Figure 4). All capture antibodies have been validated for human targets. Although this kit has not been tested with mouse lysates, it is expected than many capture antibodies will crossreact in murine systems.


Receptor Tyrosine Kinases (RTKs) are a family of cell surface receptors that signal primarily through tyrosine phosphorylation events (1). RTKs trigger a wide range of downstream signaling cascades, including the PI3K/Akt, MAPK and Jak/Stat pathways. These pathways control basic cellular functions such as division, growth, metabolism, differentiation, migration and survival. Dysregulation of RTK signaling has been implicated in a large number of cancers (2), making RTKs popular targets for pharmaceutical intervention.


1.  Schlessinger, J. (2000) Cell 103, 211-25.

2.  Blume-Jensen, P. and Hunter, T. (2001) Nature 411, 355-65.

3.  Looyenga, B.D. et al. (2012) PLoS One 7, e30820.


Entrez-Gene Id 25 , 207 , 208 , 10000 , 238 , 558 , 1436 , 1956 , 2041 , 1969 , 2042 , 2049 , 2050 , 5595 , 5594 , 2260 , 2264 , 2534 , 3055 , 2064 , 2065 , 3480 , 3643 , 3667 , 3815 , 3932 , 4067 , 4233 , 5156 , 5979 , 4486 , 6714 , 6772 , 6774 , 6194 , 7010 , 4914 , 4915 , 7301 , 3791 , 7525 , 7535

Protein Specific References

di Bari MG et al. (2006) EMBO Rep 7, 727–33

Chen S et al. (2008) J Mol Biol 383, 414–23

Nihira K et al. (2008) Oncogene 27, 7285–95

Germack R and Dickenson JM (2000) Br J Pharmacol 130, 867–74

Wick MJ et al. (2000) J Biol Chem 275, 40400–6

Rane MJ et al. (2001) J Biol Chem 276, 3517–23

Guizzetti M and Costa LG (2001) Neuroreport 12, 1639–42

Brognard J et al. (2001) Cancer Res 61, 3986–97

Maira SM et al. (2001) Science 294, 374–80

Schönherr E et al. (2001) J Biol Chem 276, 40687–92

Hill MM et al. (2001) J Biol Chem 276, 25643–6

Dhawan P et al. (2002) Cancer Res 62, 7335–42

Conus NM et al. (2002) J Biol Chem 277, 38021–8

Sano H et al. (2002) J Biol Chem 277, 19439–47

Egawa K et al. (2002) J Biol Chem 277, 38863–9

Kisseleva MV et al. (2002) J Biol Chem 277, 6266–72

Barry FA and Gibbins JM (2002) J Biol Chem 277, 12874–8

Ikonomov OC et al. (2002) Endocrinology 143, 4742–54

Rani MR et al. (2002) J Biol Chem 277, 38456–61

Ho R et al. (2002) Cancer Res 62, 6462–6

Wan X and Helman LJ (2003) Oncogene 22, 8205–11

Fukuda T et al. (2003) J Biol Chem 278, 51324–33

Kim HH et al. (2003) FASEB J 17, 2163–5

Min YH et al. (2004) Cancer Res 64, 5225–31

Tazzari PL et al. (2004) Br J Haematol 126, 675–81

Matsuzaki H et al. (2004) Biochemistry 43, 4284–93

Wolfrum S et al. (2004) Arterioscler Thromb Vasc Biol 24, 1842–7

Kaneko Y et al. (2004) J Cell Sci 117, 407–15

Esfandiarei M et al. (2004) J Virol 78, 4289–98

Baudhuin LM et al. (2004) FASEB J 18, 341–3

Dietze EC et al. (2004) Oncogene 23, 3851–62

Wu T et al. (2004) Mol Cancer Ther 3, 299–307

Honjo S et al. (2005) DNA Cell Biol 24, 141–7

Karlsson HK et al. (2005) Diabetes 54, 1459–67

Viniegra JG et al. (2005) J Biol Chem 280, 4029–36

Le XF et al. (2005) J Biol Chem 280, 2092–104

Smith E and Frenkel B (2005) J Biol Chem 280, 2388–94

Edwards LA et al. (2005) Oncogene 24, 3596–605

Karlsson HK et al. (2005) Diabetes 54, 1692–7

Kippenberger S et al. (2005) J Biol Chem 280, 3060–7

Jung HS et al. (2005) Mol Endocrinol 19, 2748–59

Khundmiri SJ et al. (2006) Am J Physiol Cell Physiol 291, C1247–57

Hers I and (2007) Blood 110, 4243–52

Ananthanarayanan B et al. (2007) J Biol Chem 282, 36634–41

Zunder ER et al. (2008) Cancer Cell 14, 180–92

Grenegård M et al. (2008) J Biol Chem 283, 18493–504

Abubaker J et al. (2009) Mol Cancer 8, 51

Chen PL and Easton AS (2011) Curr Neurovasc Res 8, 14–24

Van Aller GS et al. (2011) Biochem Biophys Res Commun 406, 194–9

Uesugi A et al. (2011) Cancer Res 71, 5765–78

Ou YH et al. (2011) Mol Cell 41, 458–70

Wang S et al. (2012) PLoS One 7, e37427

Glidden EJ et al. (2012) J Biol Chem 287, 581–8

Shih MC et al. (2012) Oncogene 31, 2389–400

Misra UK and Pizzo SV (2012) J Cell Biochem 113, 1488–500

Germack R and Dickenson JM (2000) Br J Pharmacol 130, 867–74

Wick MJ et al. (2000) J Biol Chem 275, 40400–6

Rane MJ et al. (2001) J Biol Chem 276, 3517–23

Guizzetti M and Costa LG (2001) Neuroreport 12, 1639–42

Brognard J et al. (2001) Cancer Res 61, 3986–97

Maira SM et al. (2001) Science 294, 374–80

Schönherr E et al. (2001) J Biol Chem 276, 40687–92

Hill MM et al. (2001) J Biol Chem 276, 25643–6

Dhawan P et al. (2002) Cancer Res 62, 7335–42

Conus NM et al. (2002) J Biol Chem 277, 38021–8

Sano H et al. (2002) J Biol Chem 277, 19439–47

Egawa K et al. (2002) J Biol Chem 277, 38863–9

Kisseleva MV et al. (2002) J Biol Chem 277, 6266–72

Barry FA and Gibbins JM (2002) J Biol Chem 277, 12874–8

Ikonomov OC et al. (2002) Endocrinology 143, 4742–54

Rani MR et al. (2002) J Biol Chem 277, 38456–61

Ho R et al. (2002) Cancer Res 62, 6462–6

Wan X and Helman LJ (2003) Oncogene 22, 8205–11

Fukuda T et al. (2003) J Biol Chem 278, 51324–33

Kim HH et al. (2003) FASEB J 17, 2163–5

Min YH et al. (2004) Cancer Res 64, 5225–31

Tazzari PL et al. (2004) Br J Haematol 126, 675–81

Matsuzaki H et al. (2004) Biochemistry 43, 4284–93

Wolfrum S et al. (2004) Arterioscler Thromb Vasc Biol 24, 1842–7

Kaneko Y et al. (2004) J Cell Sci 117, 407–15

Esfandiarei M et al. (2004) J Virol 78, 4289–98

Baudhuin LM et al. (2004) FASEB J 18, 341–3

Dietze EC et al. (2004) Oncogene 23, 3851–62

Wu T et al. (2004) Mol Cancer Ther 3, 299–307

Honjo S et al. (2005) DNA Cell Biol 24, 141–7

Karlsson HK et al. (2005) Diabetes 54, 1459–67

Viniegra JG et al. (2005) J Biol Chem 280, 4029–36

Le XF et al. (2005) J Biol Chem 280, 2092–104

Smith E and Frenkel B (2005) J Biol Chem 280, 2388–94

Edwards LA et al. (2005) Oncogene 24, 3596–605

Karlsson HK et al. (2005) Diabetes 54, 1692–7

Kippenberger S et al. (2005) J Biol Chem 280, 3060–7

Jung HS et al. (2005) Mol Endocrinol 19, 2748–59

Khundmiri SJ et al. (2006) Am J Physiol Cell Physiol 291, C1247–57

Hers I and (2007) Blood 110, 4243–52

Ananthanarayanan B et al. (2007) J Biol Chem 282, 36634–41

Zunder ER et al. (2008) Cancer Cell 14, 180–92

Grenegård M et al. (2008) J Biol Chem 283, 18493–504

Abubaker J et al. (2009) Mol Cancer 8, 51

Chen PL and Easton AS (2011) Curr Neurovasc Res 8, 14–24

Van Aller GS et al. (2011) Biochem Biophys Res Commun 406, 194–9

Uesugi A et al. (2011) Cancer Res 71, 5765–78

Ou YH et al. (2011) Mol Cell 41, 458–70

Wang S et al. (2012) PLoS One 7, e37427

Glidden EJ et al. (2012) J Biol Chem 287, 581–8

Shih MC et al. (2012) Oncogene 31, 2389–400

Misra UK and Pizzo SV (2012) J Cell Biochem 113, 1488–500

Germack R and Dickenson JM (2000) Br J Pharmacol 130, 867–74

Wick MJ et al. (2000) J Biol Chem 275, 40400–6

Rane MJ et al. (2001) J Biol Chem 276, 3517–23

Guizzetti M and Costa LG (2001) Neuroreport 12, 1639–42

Brognard J et al. (2001) Cancer Res 61, 3986–97

Maira SM et al. (2001) Science 294, 374–80

Schönherr E et al. (2001) J Biol Chem 276, 40687–92

Hill MM et al. (2001) J Biol Chem 276, 25643–6

Dhawan P et al. (2002) Cancer Res 62, 7335–42

Conus NM et al. (2002) J Biol Chem 277, 38021–8

Sano H et al. (2002) J Biol Chem 277, 19439–47

Egawa K et al. (2002) J Biol Chem 277, 38863–9

Kisseleva MV et al. (2002) J Biol Chem 277, 6266–72

Barry FA and Gibbins JM (2002) J Biol Chem 277, 12874–8

Ikonomov OC et al. (2002) Endocrinology 143, 4742–54

Rani MR et al. (2002) J Biol Chem 277, 38456–61

Ho R et al. (2002) Cancer Res 62, 6462–6

Wan X and Helman LJ (2003) Oncogene 22, 8205–11

Fukuda T et al. (2003) J Biol Chem 278, 51324–33

Kim HH et al. (2003) FASEB J 17, 2163–5

Min YH et al. (2004) Cancer Res 64, 5225–31

Tazzari PL et al. (2004) Br J Haematol 126, 675–81

Matsuzaki H et al. (2004) Biochemistry 43, 4284–93

Wolfrum S et al. (2004) Arterioscler Thromb Vasc Biol 24, 1842–7

Kaneko Y et al. (2004) J Cell Sci 117, 407–15

Esfandiarei M et al. (2004) J Virol 78, 4289–98

Baudhuin LM et al. (2004) FASEB J 18, 341–3

Dietze EC et al. (2004) Oncogene 23, 3851–62

Wu T et al. (2004) Mol Cancer Ther 3, 299–307

Honjo S et al. (2005) DNA Cell Biol 24, 141–7

Karlsson HK et al. (2005) Diabetes 54, 1459–67

Viniegra JG et al. (2005) J Biol Chem 280, 4029–36

Le XF et al. (2005) J Biol Chem 280, 2092–104

Smith E and Frenkel B (2005) J Biol Chem 280, 2388–94

Edwards LA et al. (2005) Oncogene 24, 3596–605

Karlsson HK et al. (2005) Diabetes 54, 1692–7

Kippenberger S et al. (2005) J Biol Chem 280, 3060–7

Jung HS et al. (2005) Mol Endocrinol 19, 2748–59

Khundmiri SJ et al. (2006) Am J Physiol Cell Physiol 291, C1247–57

Hers I and (2007) Blood 110, 4243–52

Ananthanarayanan B et al. (2007) J Biol Chem 282, 36634–41

Zunder ER et al. (2008) Cancer Cell 14, 180–92

Grenegård M et al. (2008) J Biol Chem 283, 18493–504

Abubaker J et al. (2009) Mol Cancer 8, 51

Chen PL and Easton AS (2011) Curr Neurovasc Res 8, 14–24

Van Aller GS et al. (2011) Biochem Biophys Res Commun 406, 194–9

Uesugi A et al. (2011) Cancer Res 71, 5765–78

Ou YH et al. (2011) Mol Cell 41, 458–70

Wang S et al. (2012) PLoS One 7, e37427

Glidden EJ et al. (2012) J Biol Chem 287, 581–8

Shih MC et al. (2012) Oncogene 31, 2389–400

Misra UK and Pizzo SV (2012) J Cell Biochem 113, 1488–500

Johnson AL et al. (2001) Biol Reprod 64, 1566–74

Zhang M and Riedel H (2009) J Cell Biochem 107, 65–75

Johnson AL et al. (2001) Biol Reprod 64, 1566–74

Zhang M and Riedel H (2009) J Cell Biochem 107, 65–75

Johnson AL et al. (2001) Biol Reprod 64, 1566–74

Zhang M and Riedel H (2009) J Cell Biochem 107, 65–75

Heimberger AB et al. (2002) Clin Cancer Res 8, 3496–502

Chen X and Resh MD (2002) J Biol Chem 277, 49631–7

Ravid T et al. (2002) J Biol Chem 277, 31214–9

Westover EJ et al. (2003) J Biol Chem 278, 51125–33

Agazie YM and Hayman MJ (2003) Mol Cell Biol 23, 7875–86

Saito T et al. (2004) Endocrinology 145, 4232–43

Pao W et al. (2004) Proc Natl Acad Sci U S A 101, 13306–11

Mattila E et al. (2005) Nat Cell Biol 7, 78–85

Tanos B and Pendergast AM (2006) J Biol Chem 281, 32714–23

Huang F et al. (2006) Mol Cell 21, 737–48

Wu SL et al. (2006) Mol Cell Proteomics 5, 1610–27

Kannangai R et al. (2006) Mod Pathol 19, 1456–61

Sonnweber B et al. (2006) J Clin Pathol 59, 255–9

Riggins RB et al. (2006) Cancer Res 66, 7007–15

Huang F et al. (2007) Proc Natl Acad Sci U S A 104, 16904–9

Tong J et al. (2009) Mol Cell Proteomics 8, 2131–44

Goh LK et al. (2010) J Cell Biol 189, 871–83

Hall EH et al. (2011) Cell Signal 23, 1972–7

Huang WC et al. (2011) J Biol Chem 286, 20558–68

Cotton CU et al. (2013) Traffic 14, 337–54

Syme CA et al. (2005) J Biol Chem 280, 11281–8

Syme CA et al. (2005) J Biol Chem 280, 11281–8

Li Z et al. (2001) J Biol Chem 276, 42226–32

Li Z et al. (2001) J Biol Chem 276, 42226–32

Nguyen TH et al. (2002) J Biol Chem 277, 24274–9

Dankort D et al. (2001) Mol Cell Biol 21, 1540–51

Ren Z and Schaefer TS (2002) J Biol Chem 277, 38486–93

Marone R et al. (2004) Nat Cell Biol 6, 515–22

Montgomery RB et al. (2005) Cancer Res 65, 650–6

Bose R et al. (2006) Proc Natl Acad Sci U S A 103, 9773–8

Xu W et al. (2007) Mol Cell Biol 27, 220–8

Northey JJ et al. (2008) Mol Cell Biol 28, 3162–76

Frogne T et al. (2009) Breast Cancer Res 11, R11

Werner ED et al. (2004) J Biol Chem 279, 35298–305

Batty IH et al. (2004) Biochem J 379, 641–51

Danielsson A et al. (2005) J Biol Chem 280, 34389–92

Shah OJ and Hunter T (2006) Mol Cell Biol 26, 6425–34

del Rincón, S.V. et al. (2004) Oncogene 23, 9269-79.

Lennartsson J et al. (2003) Exp Cell Res 288, 110–8

Alonso A et al. (2004) J Biol Chem 279, 4922–8

Chichili GR and Rodgers W (2007) J Biol Chem 282, 36682–91

Wagner MJ and Smiley JR (2009) J Virol 83, 12452–61

Motiwala T et al. (2010) J Cell Biochem 110, 846–56

Jin LL et al. (2010) J Proteome Res 9, 2752–61

Maulik G et al. (2002) J Cell Mol Med 6, 539–53

Lock LS et al. (2003) J Biol Chem 278, 30083–90

Palka HL et al. (2003) J Biol Chem 278, 5728–35

Hov H et al. (2004) Clin Cancer Res 10, 6686–94

Deheuninck J et al. (2009) Cell Signal 21, 1455–63

Pavone LM et al. (2011) Cell Signal 23, 1961–71

Nakayama M et al. (2013) Cytokine 62, 446–52

Hayashi H et al. (2000) Oncogene 19, 4469–75

Besset V et al. (2000) J Biol Chem 275, 39159–66

De Vita G et al. (2000) Cancer Res 60, 3727–31

Fukuda T et al. (2002) J Biol Chem 277, 19114–21

Castellone MD et al. (2003) Oncogene 22, 246–55

Crowder RJ et al. (2004) J Biol Chem 279, 42072–81

Plaza Menacho I et al. (2005) Cancer Res 65, 1729–37

Runeberg-Roos P et al. (2007) Oncogene 26, 7909–15

Toledo RA et al. (2010) J Clin Endocrinol Metab 95, 1318–27

Perrinjaquet M et al. (2010) J Biol Chem 285, 31867–75

Li XZ et al. (2012) J Biol Chem 287, 1932–45

Wang YH et al. (2001) Am J Physiol Cell Physiol 281, C1667–75

Schmitt JM and Stork PJ (2002) Mol Cell 9, 85–94

Zhou J et al. (2003) J Biol Chem 278, 6936–41

Abrahamsen H et al. (2003) J Biol Chem 278, 17170–7

Kim M et al. (2004) Oncogene 23, 1645–55

Zhou S et al. (2004) J Biol Chem 279, 54463–9

Ren Y et al. (2004) J Biol Chem 279, 8497–505

Kim HP et al. (2004) Biochem J 379, 141–50

Feistritzer C et al. (2005) Exp Cell Res 305, 214–20

Daoud G et al. (2006) J Physiol 571, 537–53

Eichhorn PJ et al. (2007) PLoS Genet 3, e218

Zhu S et al. (2007) Cancer Res 67, 10129–37

Dimberg A et al. (2000) Blood 96, 2870–8

Mowen KA et al. (2001) Cell 104, 731–41

Zhu W et al. (2002) J Biol Chem 277, 35787–90

Chen Q et al. (2002) Immunology 107, 199–208

Nair JS et al. (2002) Proc Natl Acad Sci U S A 99, 5971–6

DeVries TA et al. (2004) J Biol Chem 279, 45603–12

Timofeeva OA et al. (2006) Oncogene 25, 7555–64

Liu X et al. (2008) J Immunol 181, 449–63

Vanhatupa S et al. (2008) Biochem J 409, 179–85

Roth A et al. (2010) Proc Natl Acad Sci U S A 107, 19502–7

Chen Z et al. (2011) Cell Signal 23, 1404–12

Antunes F et al. (2011) Mol Cell Biol 31, 3029–37

Grönholm J et al. (2012) BMC Biochem 13, 20

Dimberg A et al. (2000) Blood 96, 2870–8

Mowen KA et al. (2001) Cell 104, 731–41

Zhu W et al. (2002) J Biol Chem 277, 35787–90

Chen Q et al. (2002) Immunology 107, 199–208

Nair JS et al. (2002) Proc Natl Acad Sci U S A 99, 5971–6

DeVries TA et al. (2004) J Biol Chem 279, 45603–12

Timofeeva OA et al. (2006) Oncogene 25, 7555–64

Liu X et al. (2008) J Immunol 181, 449–63

Vanhatupa S et al. (2008) Biochem J 409, 179–85

Roth A et al. (2010) Proc Natl Acad Sci U S A 107, 19502–7

Chen Z et al. (2011) Cell Signal 23, 1404–12

Antunes F et al. (2011) Mol Cell Biol 31, 3029–37

Grönholm J et al. (2012) BMC Biochem 13, 20

Ng J and Cantrell D (1997) J Biol Chem 272, 24542–9

Schuringa JJ et al. (2000) Blood 95, 3765–70

Duarte RF and Frank DA (2000) Blood 96, 3422–30

Schuringa JJ et al. (2001) Oncogene 20, 5350–8

Deb A et al. (2001) EMBO J 20, 2487–96

Abe K et al. (2001) Oncogene 20, 3464–74

Kopantzev Y et al. (2002) Oncogene 21, 6791–800

Sun S and Steinberg BM (2002) J Gen Virol 83, 1651–8

Hwang JH et al. (2003) Mol Endocrinol 17, 1155–66

Lo RK et al. (2003) J Biol Chem 278, 52154–65

Liu H et al. (2003) Blood 102, 344–52

Lo RK and Wong YH (2004) Mol Pharmacol 65, 1427–39

Wang R et al. (2005) J Biol Chem 280, 11528–34

Yuan ZL et al. (2005) Science 307, 269–73

Ray S et al. (2005) Gastroenterology 129, 1616–32

Liu AM et al. (2006) J Biol Chem 281, 35812–25

Zhang X et al. (2007) Proc Natl Acad Sci U S A 104, 4060–4

Ohbayashi N et al. (2007) Biol Pharm Bull 30, 1860–4

Nadiminty N et al. (2007) Biochem Biophys Res Commun 359, 379–84

Duechting A et al. (2008) J Virol 82, 7942–52

Chen CL et al. (2008) Mol Cancer 7, 78

Hatziapostolou M et al. (2011) Cell 147, 1233–47

Sestito R et al. (2011) FASEB J 25, 916–27

Gupta M et al. (2012) Leukemia 26, 1356–64

Perl AE et al. (2012) Clin Cancer Res 18, 1716–25

Sturk C and Dumont DJ (2010) Cell Commun Signal 8, 30


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
PathScan® is a trademark of Cell Signaling Technology, Inc.
DyLight™ is a trademark of Thermo Fisher Scientific, Inc. and its subsidiaries.